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ABSTRACT
Background and Objectives: The ability to obtain adequate tissue of solid pancreatic lesions by EUS‑guided remains a
challenge. The aim of this study was to compare the performance characteristics and safety of EUS‑FNA for evaluating solid
pancreatic lesions using the standard 22‑gauge needle versus a novel EUS biopsy needle. Methods: This was a multicenter
retrospective study of EUS‑guided sampling of solid pancreatic lesions between 2009 and 2015. Patients underwent
EUS‑guided sampling with a 22‑gauge SharkCore (SC) needle or a standard 22‑gauge FNA needle. Technical success,
performance characteristics of EUS‑FNA, the number of needle passes required to obtain a diagnosis, diagnostic accuracy,
and complications were compared. Results: A total of 1088 patients (mean age = 66 years; 49% female) with pancreatic
masses underwent EUS‑guided sampling with a 22‑gauge SC needle (n = 115) or a standard 22‑gauge FNA needle (n = 973).
Technical success was 100%. The frequency of obtaining an adequate cytology by EUS‑FNA was similar when using the SC
and the standard needle (94.1% vs. 92.7%, respectively). The sensitivity, specificity, and diagnostic accuracy of EUS‑FNA
for tissue diagnosis were not significantly different between two needles. Adequate sample collection leading to a definite
diagnosis was achieved by the 1st, 2nd, and 3rd pass in 73%, 92%, and 98% of procedures using the SC needle and 20%, 37%,
and 94% procedures using the standard needle (P < 0.001), respectively. The median number of passes to obtain a tissue
diagnosis using the SC needle was significantly less as compared to the standard needle (1 and 3, respectively; P < 0.001).
Conclusions: The EUS SC biopsy needle is safe and technically feasible for EUS‑FNA of solid pancreatic mass lesions.
Preliminary results suggest that the SC needle has a diagnostic yield similar to the standard EUS needle and significantly
reduces the number of needle passes required to obtain a tissue diagnosis.
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INTRODUCTION

METHODS

The incidence of pancreatic cancer has been steadily
increasing over the past decade. Approximately 53,000
new cases of pancreatic cancer will be diagnosed in
2016, with pancreatic cancer projected to surpass breast
cancer as the third leading cause of cancer‑related
death in the United States. With a 5‑year survival rate
of only 8%, early and accurate pathological diagnosis
is vital to guide subsequent patient management.[1] In
patients with a suspicious pancreatic lesion, EUS‑FNA
allows for tissue acquisition and cytological verification
of malignancy and is the current standard for diagnosis
at most centers. The diagnostic accuracy of EUS‑FNA
varies from 78% to 95%. [2‑4] As evidenced in the
literature, several factors are known to influence the
diagnostic accuracy of EUS‑FNA, including diameter
of needle, number of passes required, and presence
of a cytopathologist who can provide rapid on‑site
evaluation (ROSE).[5‑10] Increased expense and resources
associated with ROSE have been an obstacle to the
universal implementation of this technique, and in the
absence of ROSE, multiple passes are often needed to
acquire adequate tissue.[11,12]

Patient selection

New EUS fine‑needle biopsy (EUS‑FNB) designs
in recent years have advanced the ability to
obtain adequate core tissue with preserved tissue
architecture for histological analysis. [13‑17] A recent
meta‑analysis found the sensitivity and specificity
of EUS‑FNB in differentiating malignant from
benign pancreatic masses to be 0.84 (95% confidence
interval [CI], 0.82–0.87) and 0.98 (95% CI, 0.93–1.00),
respectively.[18] Except decreased number of needles
passes, studies have failed to show a diagnostic
advantage in using EUS‑FNB needles over standard
EUS‑FNA needles.[19,20]
A recent tissue acquisition device to gain FDA approval
is the SharkCore™ FNB device (SC‑FNB), used as part
of the Beacon EUS Delivery System (Medtronic). Initial
experience with the novel EUS core biopsy needle has
been promising with pathologic diagnostic yield of 87%
for pancreatic lesions.[21]
The objective of this multicenter retrospective
cohort study was to compare the perfor mance
characteristics and safety of the standard 22‑guage EUS
needle (EUS‑FNA) versus the EUS 22‑gauge SC‑FNB
for the diagnosis of solid pancreatic lesions.

We conducted a dual‑center retrospective cohort
study of all EUS‑guided sampling of solid pancreatic
lesions performed between June 2009 and October
2015. ROSE was available for all procedures. During
the study, a total of 1088 consecutive patients with
solid pancreatic lesions underwent EUS‑guided
sampling with either a 22‑gauge SC‑FNB or 22‑gauge
FNA needle (EchoTip Ultra 3 needle; Wilson‑Cook
Medical, Winston‑Salem, North Carolina) for
diagnosis depending on the year of their presentation
(the 22‑gauge SC‑FNB needle was introduced at our
institutions in February 2013 and since that time has
been used exclusively for all EUS‑guided sampling).
The medical records of the patients were reviewed
using a standard data entry for m that included
patients’ demographics, technical success, performance
characteristics of EUS‑FNA, location of lesion, size,
number of needle passes required to obtain a diagnosis,
cytology results, and procedural complications. The
results of EUS‑guided sampling were confirmed using
surgical histopathology when available. This study was
approved by the Institutional Review Board of the
participating institutions.

EUS guided sampling technique

All EUS‑FNAs were performed by experienced faculty
who had perfor med >500 EUS procedures. The
pancreatic lesion was initially identified using the
curvilinear echoendoscope (Olympus GF‑UCT180, 160,
or 140, Center Valley, PA) after which the EUS‑FNA
was performed. Lesions were sampled with either a
transgastric or transduodenal approach based on lesion
location. As previously mentioned, either the 22‑gauge
SC‑FNB needle or the standard 22‑gauge FNA needle
was used to sample the target lesion.

Technique for using the 22‑gauge EUS-FNA needle

The 22‑gauge EUS‑FNA needle device was passed
through the echoendoscope biopsy channel and then
advanced into a target lesion under ultrasound guidance
with the stylet within the needle. The stylet was removed
and 10 cc of suction was applied. Ten actuations were
performed. Suction was released before removal of
the needle to avoid contamination of GI mucosa.
Aspirated cellular material was expressed onto the slide
by advancing the stylet, and the remainder was expressed
into a cell block preparation using saline or air flush.
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Technique for using the 22‑gauge EUS-FNA
SharkCore™ needle

Targets were localized on EUS and punctured with
the stylet in place. The stylet was pulled back 5 cm
from the needle tip and the needle was held in place
for 30 s. Four actuations were performed. The stylet
was completely removed and four more actuations
were performed. The needle was withdrawn from the
mass without the application of suction. Aspirated
cellular material was expressed onto a slide using an
air‑filled 10 cc syringe.

Cytological preparation

Aspirates were placed onto glass slides and preserved
with Diff‑Quik stain (American Scientific Products,
McGraw Park, Illinois, USA). In addition, a smear was
also placed in alcohol for Papanicolaou staining. Any
additional material was sent for cell block processing.
The cytology technician on‑site verified adequacy of
specimens. Each cytological aspirate obtained by either
the SC‑FNB or EUS‑FNA needle was evaluated by
an expert cytopathologist for ROSE and classified as
malignant, benign, or an inadequate specimen based on
cytological smear. A specimen was considered adequate
if there were an adequate number of representative
cells from the target lesion.

Cytologic assessment of samples

Patients in the current study were classified as having
a benign versus a malignant lesion. A final diagnosis
of a pancreatic malignancy was based on (1) cytologic
or histologic evidence of malignancy based on
material obtained using EUS‑FNA, ERCP, surgical or
percutaneous biopsy OR (2) clinical course based on
follow‑up in which that patient developed radiographic
evidence of local or distant metastasis, or death
attributed to a malignant pancreatic lesion based on
clinical records if the cytology or surgical pathology
results were inconclusive. A lesion was defined as being
benign based on EUS‑FNA results, clinical follow‑up,
and lack of disease progression over a period of at
least 6 months. When a final diagnosis could not be
established due to the lack of a criterion standard or
adequate follow‑up (n = 42), patients were excluded
when calculating operating characteristics.
EUS‑FNA cytology samples were interpreted as
malignant, suspicious for malignancy, atypical cells,
benign, and nondiagnostic. Patients with suspicious
or malignant cytology were classified as “true positive
“if the final diagnosis was malignancy, and those
36

considered benign on the final diagnosis were classified
as “false positive.” [14] Similarly, lesions classified as
benign by EUS‑FNA with a final diagnosis of benign
were considered “true negative” and those considered
malignant on final diagnosis were false negative.
Atypical cytology with final diagnosis as benign was
considered “true negative” and those malignant as “false
negative.”
Diagnostic accuracy was defined as the ratio between
the sum of true positive and true negative values,
divided by the total number of samples. The adequacy
rate was calculated by the following formula: number of
adequate samples divided by total number of samples.

Statistical analysis

Patients were stratified into two groups: (1) those that
underwent sampling of the pancreatic lesion using
the 22‑gauge EUS‑FNA Needle and (2) those that
underwent sampling using the 22‑gauge EUS‑FNB.
Summary statistics were calculated in the two groups,
using means and standard deviations for continuous
variables and counts and percentages for categorical
variables.
A two‑tailed sample size calculation was performed with
the type I error rate (α) set at 0.05 to attain 80% power
for a 20% difference in diagnostic yield for each pass.
The targeted sample size needed was 46 patients in the
FNA group and 46 patients in the FNB group.
The overall operating characteristics of each needle
were analyzed for sensitivity, specificity, positive
predictive value (PPV), negative predictive value (NPV),
and diagnostic accuracy. Proportions were compared
using a Z‑test. Each pass was analyzed for adequacy
and an odds ratio was calculated. The mean number of
needle passes needed to achieve diagnosis on cytological
smear was analyzed with a two‑tailed‑t‑test. Statistical
significance was taken as P < 0.05. Statistical analyses
were performed using SAS 9.3 (SAS Institute Inc., Cary,
North Carolina, USA).
RESULTS
A total of 1088 patients (Thomas Jefferson
University = 1026 patients and University of
Utah = 62 patients) underwent EUS‑guided sampling
for the evaluation of solid pancreatic mass lesions.
Of these patients, 973 underwent EUS‑FNA using
the standard 22‑gauge FNA needle, whereas the
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22‑gauge SC‑FNB needle was utilized in 115 patients.
Demographic data of the study population and
characteristics of the mass lesions are shown in
Table 1. The mean age of subjects was 66 years, and
49% were female. Totally, 814 lesions were located in
the head/uncinate process of the pancreas, 185 were
in the pancreatic body, and 89 were in the pancreatic
tail. The mean lesion size was 29 mm (range 7–83).
There was no significant difference between the two
groups with regard to gender, age, lesion size, or
location.
Surgical histopathology was available 301 (31%) patients
in the 22‑gauge FNA group and 26 (30%) cases in the
22‑gauge SC‑FNB group. The final pathology diagnosis
was adenocarcinoma in 81.8% of cases, neuroendocrine
tumor 4.7%, intra‑ductal papillary mucosal neoplasms
with dysplasia in 5.4%, metastatic disease in 4.4%, and
benign cells in 3.7%. Approximately one‑third of the
patients (327; 30%) with a pancreatic mass underwent
successful curative surgery which further confirmed the
diagnosis of malignancy.

The procedural technical success rate was 100% in
both groups. There was no significant difference in the
ability to obtain adequate tissue cytology when using
the SC‑FNB and the standard FNA needle (94.1% and
92.7%, respectively; P = 0.85).
Operating characteristics of the individual EUS needles
are summarized in Table 2. Both groups showed high
sensitivities and specificities. The FNB needle had a
higher sensitivity to diagnose malignancy compared to
the 22‑gauge standard FNA needle (98% vs. 91.5%,
respectively; P = 0.077); this difference approached but
did not reach statistical significance. Both groups had
similar specificities (P = 0.98). The FNB and standard
FNA needle both had a high PPV to diagnose a
cancer (98% vs. 99.7%; P = 0.99). Conversely, the FNB
needle had a significantly superior NPV to diagnose
a cancer (97.5%) as compared to the standard FNA
needle (53.7%) (P = 0.0001). Although the diagnostic
accuracy of the FNB was also superior compared to
the standard FNA needle, this did not reach statistical
significance (96.5% vs. 92%, respectively; P = 0.167).

Table 1. Baseline demographic characteristics of study cohort
P

Mean (SD)
22‑gauge standard
FNA needle (n=973)

22‑gauge SharkCore™
FNB needle (n=115)

66.7
25.9
3
496 (51)

66.1
27.5
1
57 (50)

0.72
0.42
<0.001*
1

721
172
80

93
13
9

0.14
0.09
1

867
35
71

103
5
7

1
0.6
0.85

90.3
9.7

87.5
12.5

0.41

Age
Tumor size, largest dimension (mm)
Median number of EUS‑FNA passes to obtain diagnosis
Sex, male (%)
Tumor location
Head/uncinate
Body
Tail
Overall EUS acquired cytology results
Positive/suspicious
Benign
Insufficient tissue
Overall final diagnosis (%)
Malignant
Benign
FNB: Fine‑needle biopsy, SD: Standard deviation, *: Statistically significant

Table 2. Operating characteristics of individual EUS needles
Operating characteristics

Technique of EUS tissue acquisition
22‑gauge standard FNA
needle (n=973) (%)

Sensitivity (95% CI)
Specificity (95% CI)
PPV (95% CI)
NPV (95% CI)
Diagnostic accuracy (95% CI)

91.5 (89.6–93.4)
97.6 (94.2–100.0)
99.7 (99.4–100.0)
53.7 (45.7–61.7)
92.0 (90.3–93.8)

P

22‑gauge SharkCore™
FNB needle (n=115) (%)
98.0
87.5
98.0
87.5
96.5

(94.0–100.0)
(64.6–100.0)
(94.0–100.0)
(64.6–100.0)
(91.7–100.0)

0.077
0.18
0.989
0.0001‡
0.167

FNB: Fine‑needle biopsy, CI: Confidence interval, PPV: Positive predictive value, NPV: Negative predictive value. ‡: Statistically significant
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The per pass analysis for the two different needles is
shown in Table 3 as analyzed by a Poisson regression.
Adequate sample collection leading to a definite
diagnosis was achieved by the 1st, 2nd, and 3rd passes in
73%, 92%, and 98% of procedures, respectively, when
using the SC needle, as opposed to and 20%, 37%, and
94% procedures, respectively, when using the standard
needle (P < 0.001). The median number of passes
to obtain a tissue diagnosis using the SC needle was
significantly less as compared to the standard needle
(1 and 3, respectively; P < 0.001).
The overall rates in the FNB and standard FNA
needle were 2 (1.7%) versus 12 (1.2%) (P = 0.65).
Complications of the FNB group were post‑FNA
pancreatitis (n = 2). Complications of the standard
FNA needle group were post‑FNA pancreatitis (n = 5),
self‑limited abdominal pain (n = 4), and minor bleeding
after FNA (n = 3).
DISCUSSION
In the absence of ROSE, inadequate specimens are
obtained in as many as 29% of patients who undergo
EUS‑FNA.[22] While historical data have cited a low
rate of false positive diagnosis of malignancy (0%–1%),
recent studies suggest that the false positive rate of
FNA cytology is as high as 5%–7%.[23‑25] Studies have
also reported up to 30% of patients with clinical and
imaging findings suggestive of pancreatic malignancy
having negative cytology on EUS‑FNA. [26,27] To
overcome these limitations of cytological aspirates,
novel EUS core biopsy needles have been developed in
efforts to reliably obtain intact core tissue and increase
specimen adequacy and diagnosis, thereby obviating or
at least reducing the need for and dependence on an
onsite cytopathologist.
Although
initial
studies
of
both
the
first‑generation (Quick‑Core, Cook Medical
Inc., Winston Salem, North Carolina) and
second‑generation (ProCore, Cook Endoscopy)
core biopsy needles were promising, additional
studies have failed to demonstrate a diagnostic

advantage of either needle over standard EUS‑FNA
needles.[19,28,29] Furthermore, design limitation and lack
of maneuverability of the tru‑cut biopsy needle have
largely limited its use in clinical practice.[30]
To the best of our knowledge, our multicenter
retrospective cohort study is the largest study to
date to evaluate the diagnostic yield (with respect to
cytological aspirate) and performance of the SC FNB
against the standard 22‑gauge FNA needle. Our study
failed to demonstrate the superiority of the SC needle
over the standard needle in terms of overall diagnostic
accuracy. However, it was noted that fewer passes were
required in the FNB group to establish a pathologic
diagnosis. This finding is in keeping with results
obtained by previous studies that have demonstrated
that while the ProCore FNB needle had a similar
diagnostic accuracy to the 22‑gauge standard EUS
needle, fewer passes were required to achieve diagnostic
adequacy.[19,31,32]
This finding is significant in its implications for patient
safety and cost efficiency, as fewer passes over many
examinations decrease risk to patients and may save
both the endoscopist and cytologist time in terms of
samples needing to be collected and processed.
Data presented in several abstracts on SC‑FNB
have demonstrated excellent pathologic as well as
diagnostic yield. Initial experience with SC‑FNB needles
from a multicenter study presented in abstract form
demonstrated a pathologic diagnostic yield of 87% for
pancreatic lesions with a minimum number of passes.
A total of 87 lesions were biopsied in 78 patients
of which 41 lesions were located in the pancreas.
A visible core was present in 95% of pancreatic lesions
biopsied (39/41) and a cytologic diagnosis was rendered
in 76% (22/29), with a median number of 2 passes
for pathology. Two patients experienced adverse events,
mild pancreatitis in a patient with a benign pancreatic
head mass (sampled with 22‑gauge SC‑FNB needle),
and abdominal pain in a patient with pancreatic head
adenocarcinoma (25G SC‑FNB needle).[21] Larsen et al.
noted the SC‑FNB needle provided a core sample for

Table 3. Per pass analysis
Pass on which diagnosis made
1
2
3 or more

SharkCore needle (n=115) (%)

Standard needle (n=973) (%)

OD (95% CI)

P

84 (73.4)
22 (18.8)
9 (7.8)

184 (18.9)
175 (18)
582 (59.8)

0.08 (0.04–0.15)
0.95 (0.49–2)
17.53 (7.01–56.49)

<0.001
0.867
<0.001

CI: Confidence interval, OD: Odds ratio
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histological evaluation in the majority of cases, with an
overall diagnostic accuracy of over 88%.[33] Similar to
our study, EUS‑FNB was technically feasible in all cases
were reported.

needles. Larger multicenter prospective trials are needed
for cost analysis and to evaluate the diagnostic accuracy
of the needle in comparison to existing needles.

In another study, Kandel et al. compared the histological
yield of EUS‑FNB sampling using the SC‑FNB needle
to EUS-FNA in patients who had solid pancreatic and
nonpancreatic lesions.[34] A total of 156 patients were
included in the study, of which 39 patients underwent
sampling using the SC‑FNB needle and 117 using the
standard EUS-FNA needle. Similar to the results of
our study, there was a statistically significant difference
in median number of passes (SC FNB, 2 passes, vs.
EUS‑FNA, 4 passes, P = 0.001). Histology yield was
also noted to be significantly higher using the SC‑FNB
needle compared with the EUS‑FNA needle (95% vs.
59%, P = 0.01).
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